$MCET APPROVED DRUG!!! *** MultiCell Technologies Phase IIB licenced candidate LAX-202 in a major deal worth USD 275 million in milestone payments and royalties. ***
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.